205 related articles for article (PubMed ID: 12825933)
1. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold.
Kissau L; Stahl P; Mazitschek R; Giannis A; Waldmann H
J Med Chem; 2003 Jul; 46(14):2917-31. PubMed ID: 12825933
[TBL] [Abstract][Full Text] [Related]
2. Traceless solid-phase synthesis of 2-aminothiazoles: receptor tyrosine kinase inhibitors with dual selectivity for Tie-2 and VEGFR-2.
Stieber F; Mazitschek R; Soric N; Giannis A; Waldmann H
Angew Chem Int Ed Engl; 2002 Dec; 41(24):4757-61. PubMed ID: 12481350
[No Abstract] [Full Text] [Related]
3. 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.
Wissner A; Floyd MB; Johnson BD; Fraser H; Ingalls C; Nittoli T; Dushin RG; Discafani C; Nilakantan R; Marini J; Ravi M; Cheung K; Tan X; Musto S; Annable T; Siegel MM; Loganzo F
J Med Chem; 2005 Dec; 48(24):7560-81. PubMed ID: 16302797
[TBL] [Abstract][Full Text] [Related]
4. Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.
Hodous BL; Geuns-Meyer SD; Hughes PE; Albrecht BK; Bellon S; Bready J; Caenepeel S; Cee VJ; Chaffee SC; Coxon A; Emery M; Fretland J; Gallant P; Gu Y; Hoffman D; Johnson RE; Kendall R; Kim JL; Long AM; Morrison M; Olivieri PR; Patel VF; Polverino A; Rose P; Tempest P; Wang L; Whittington DA; Zhao H
J Med Chem; 2007 Feb; 50(4):611-26. PubMed ID: 17253678
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.
Singh J; Dobrusin EM; Fry DW; Haske T; Whitty A; McNamara DJ
J Med Chem; 1997 Mar; 40(7):1130-5. PubMed ID: 9089334
[TBL] [Abstract][Full Text] [Related]
6. Natural product derived receptor tyrosine kinase inhibitors: identification of IGF1R, Tie-2, and VEGFR-3 inhibitors.
Stahl P; Kissau L; Mazitschek R; Giannis A; Waldmann H
Angew Chem Int Ed Engl; 2002 Apr; 41(7):1174-8. PubMed ID: 12491250
[No Abstract] [Full Text] [Related]
7. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
8. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.
Kuo GH; Wang A; Emanuel S; Deangelis A; Zhang R; Connolly PJ; Murray WV; Gruninger RH; Sechler J; Fuentes-Pesquera A; Johnson D; Middleton SA; Jolliffe L; Chen X
J Med Chem; 2005 Mar; 48(6):1886-900. PubMed ID: 15771433
[TBL] [Abstract][Full Text] [Related]
10. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
[TBL] [Abstract][Full Text] [Related]
11. Characterization and development of a peptide substrate-based phosphate transfer assay for the human vascular endothelial growth factor receptor-2 tyrosine kinase.
Zhao G; Peery RB; Yingling JM
Anal Biochem; 2007 Jan; 360(2):196-206. PubMed ID: 17141171
[TBL] [Abstract][Full Text] [Related]
12. Receptor tyrosine kinase inhibitors as anti-angiogenic agents.
Kim DW; Lu B; Hallahan DE
Curr Opin Investig Drugs; 2004 Jun; 5(6):597-604. PubMed ID: 15242247
[TBL] [Abstract][Full Text] [Related]
13. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors.
Renhowe PA; Pecchi S; Shafer CM; Machajewski TD; Jazan EM; Taylor C; Antonios-McCrea W; McBride CM; Frazier K; Wiesmann M; Lapointe GR; Feucht PH; Warne RL; Heise CC; Menezes D; Aardalen K; Ye H; He M; Le V; Vora J; Jansen JM; Wernette-Hammond ME; Harris AL
J Med Chem; 2009 Jan; 52(2):278-92. PubMed ID: 19113866
[TBL] [Abstract][Full Text] [Related]
14. A comparative cell-based high throughput screening strategy for the discovery of selective tyrosine kinase inhibitors with anticancer activity.
Stratowa C; Baum A; Castañon MJ; Dahmann G; Himmelsbach F; Himmler A; Loeber G; Metz T; Schnitzer R; Solca F; Spevak W; Tontsch U; von Rüden T
Anticancer Drug Des; 1999 Oct; 14(5):393-402. PubMed ID: 10766294
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors.
Hasegawa M; Nishigaki N; Washio Y; Kano K; Harris PA; Sato H; Mori I; West RI; Shibahara M; Toyoda H; Wang L; Nolte RT; Veal JM; Cheung M
J Med Chem; 2007 Sep; 50(18):4453-70. PubMed ID: 17676829
[TBL] [Abstract][Full Text] [Related]
16. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
[TBL] [Abstract][Full Text] [Related]
17. 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family.
Cao H; Zhang H; Zheng X; Gao D
J Mol Graph Model; 2007 Jul; 26(1):236-45. PubMed ID: 17293140
[TBL] [Abstract][Full Text] [Related]
18. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
Du J; Lei B; Qin J; Liu H; Yao X
J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
20. Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases.
Ji Z; Ahmed AA; Albert DH; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Moskey MD; Pease LJ; Stewart KD; Yates M; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2006 Aug; 16(16):4326-30. PubMed ID: 16735117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
